p53 as a target for anti-cancer drug development

被引：80

作者：

Bouchet, Benjamin Pierre ^{[1
]}

de Fromentel, Claude Caron ^{[1
]}

Puisieux, Alain ^{[1
]}

Galmarini, Carlos Maria ^{[1
]}

机构：

[1] Ctr Leon Berard, INSERM, U590, F-69373 Lyon 08, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2006年 / 58卷 / 03期

关键词：

p53; protein; apoptosis; mutation; prognosis; gene therapy; ONYX-015;

D O I：

10.1016/j.critrevonc.2005.10.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Loss of p53 function compromises genetic homeostasis in cells exhibiting deregulated DNA replication and/or DNA damage, and prevents normal cytotoxic responses to cancer therapies. Genetic and pharmacological approaches are being developed with the ultimate goal of restoring or controlling p53 functions in cancer patients. Progress has recently been made in the clinical use of replication-deficient virus carrying wt-TP53 (Ad5CMV-p53) and/or cancer-selective oncolytic adenoviruses (ONYX-015). These strategies demonstrated clinical activity as monotherapy and were synergistic with traditional chemotherapy agents in the treatment of some types of cancer. In addition, pharmacological methods are under development to either stimulate wild-type p53 protein function, or induce p53 mutant proteins to resume wild-type functions. These methods are based on small chemicals (CP-31388, PRIMA-1), peptides (CDB3) or single-chain Fv antibody fragments corresponding to defined p53 domains. Here, we discuss the mechanisms underlying these approaches and their perspectives for cancer therapy. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：190 / 207

页数：18

共 126 条

[1]

[Anonymous], 2003, BIODRUGS, V17, P216

[2] DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].

Bartkova, J ;

Horejsi, Z ;

Koed, K ;

Krämer, A ;

Tort, F ;

Zieger, K ;

Guldberg, P ;

Sehested, M ;

Nesland, JM ;

Lukas, C ;

Orntoft, T ;

Lukas, J ;

Bartek, J .

NATURE, 2005, 434 (7035) :864-870

[3] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].

Bischoff, JR ;

Kim, DH ;

Williams, A ;

Heise, C ;

Horn, S ;

Muna, M ;

Ng, L ;

Nye, JA ;

SampsonJohannes, A ;

Fattaey, A ;

McCormick, F .

SCIENCE, 1996, 274 (5286) :373-376

[4] Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].

Bottger, A ;

Bottger, V ;

Sparks, A ;

Liu, WL ;

Howard, SF ;

Lane, DP .

CURRENT BIOLOGY, 1997, 7 (11) :860-869

[5] Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2 [J].

Bougeret, C ;

Virone-Oddos, A ;

Adeline, E ;

Lacroix, F ;

Lefranc, C ;

Ferrero, L ;

Huet, T .

CANCER GENE THERAPY, 2000, 7 (05) :789-798

[6] Dominant-negative p53 mutations selected in yeast hit cancer hot spots [J].

Brachmann, RK ;

Vidal, M ;

Boeke, JD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4091-4095

[7] INFECTIONS IN 18,000 INFANTS AND CHILDREN IN A CONTROLLED STUDY OF RESPIRATORY TRACT DISEASE .I. ADENOVIRUS PATHOGENICITY IN RELATION TO SEROLOGIC TYPE AND ILLNESS SYNDROME [J].

BRANDT, CD ;

KIM, HW ;

VARGOSKO, AJ ;

JEFFRIES, BC ;

ARROBIO, JO ;

RINDGE, B ;

PARROTT, RH ;

CHANOCK, RM .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 90 (06) :484-&

[8] Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin β3 subunit expression and increased by reconstitution of integrin αVβ3 [J].

Brüning, A ;

Köhler, T ;

Quist, S ;

Wang-Gohrke, S ;

Moebus, VJ ;

Kreienberg, R ;

Runnebaum, IB .

HUMAN GENE THERAPY, 2001, 12 (04) :391-399

[9] A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer [J].

Buller, RE ;

Runnebaum, IB ;

Karlan, BY ;

Horowitz, JA ;

Shahin, M ;

Buekers, T ;

Petrauskas, S ;

Kreienberg, R ;

Slamon, D ;

Pegram, M .

CANCER GENE THERAPY, 2002, 9 (07) :553-566

[10] Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 [J].

Buller, RE ;

Shahin, MS ;

Horowitz, JA ;

Runnebaum, IB ;

Mahavni, V ;

Petrauskas, S ;

Kreienberg, R ;

Karlan, B ;

Slamon, D ;

Pegram, M .

CANCER GENE THERAPY, 2002, 9 (07) :567-572

← 1 2 3 4 5 6 7 8 9 10 →